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(Under the direction of Grace Hubbard) 
Healthcare providers engaged in medication-assisted treatment (MAT) for opioid use 
disorder frequently observe low rates of abstinence and poor patient retention within the first 
month of treatment. Can contingency management, an evidenced-based behavioral therapy, be 
implemented in an effective manner to improve upon these outcomes by promoting positive 
patient behavior and incentivizing the achievement of therapeutic goals? Using the Model for 
Improvement, a DNP project developed a contingency management protocol at an outpatient 
opioid treatment program delivering MAT. Over an implementation window of nine weeks, 3 
plan-do-study-act cycles were completed. The protocol was continuously revised, facilitating 
staff compliance and improving the effectiveness of the intervention. New patients were 
rewarded with positive reinforcement for achieving their first negative drug screen, and positive 
patient outcomes were observed to be associated with the intervention. With the final iteration of 
the protocol, the project demonstrated that contingency management may be implemented within 
MAT in a feasible, sustainable manner that encourages an optimal rate of staff compliance. The 
results of the project suggest that patients who receive contingency management after achieving 
abstinence are more likely to maintain their abstinence and remain in treatment when compared 
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CHAPTER 1: INTRODUCTION 
Despite the efforts of healthcare providers engaged in medication-assisted treatment 
(MAT) for opioid addiction in the outpatient setting, negative patient outcomes such as 
significantly low rates of abstinence and poor patient retention are frequently observed within the 
induction phase of treatment. A systematic review assessing the retention of patients receiving 
MAT among multiple settings found patient retention rates as low as 72% after one month of 
treatment, and as low as 19% after three months of treatment (Timko, Schultz, Cucciare, Vittorio, 
& Garrison-Diehn, 2016; Fullerton et al., 2014). This problem is a serious concern with the adult 
population at a local treatment center, as any factor that delays the achievement of abstinence is 
anathema to sobriety, the primary goal of substance abuse treatment. In a single month, 17 
patients were enrolled into their MAT program. A review of records indicated that of this patient 
cohort, 29% were no longer in treatment within 31 days of their induction and only 35% had 
achieved abstinence as evidenced by a negative biological indicator for illicit substances. A 
possible contributor to this problem is a lack of incentives for patients to maintain necessary 
clinical attendance and achieve their first negative drug screen, serving as evidence for 
abstinence of illicit substances. The implementation of contingency management, a form of 
behavioral therapy that rewards positive patient behavior, may improve these outcomes by 
incentivizing and promoting desired therapeutic goals leading to positive patient outcomes 
(Dugosh, Abraham, Seymour, McLoyd, Chalk, & Festinger, 2016). 
The purpose of this practice change project was the development and implementation of a 
contingency management protocol that will be guided by the Model for Improvement, an 
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evidence-based framework developed for effective quality improvement within healthcare 
settings (Institute for Healthcare Improvement, 2020). Staff compliance with the contingency 
management protocol to promote positive patient behaviors during the induction phase of 
treatment will be evaluated through retrospective chart review. The primary aim of the practice 
change is to implement contingency management with an optimal rate of staff compliance to the 
protocol. The secondary aim is to increase patient retention and abstinence of illicit substances.  
Search Strategy 
 PUBMED and CINAHL databases were used to conduct a review of literature that both 
supported the existence of the clinical problem and the effectiveness of contingency management 
as an intervention. The search queries included: 
(“buprenorphine”[Mesh] OR “methadone”[Mesh] OR “opioid-agonist”) AND (“opiate 
substitution treatment”[Mesh] OR “Opioid-Related Disorders/drug therapy”[Mesh] OR “Opioid-
Related Disorders/rehabilitation”[Mesh] AND systematic[subset]  
("Analgesics, Opioid"[Mesh] OR OPIOID OR OPIOIDS OR OPIATE OR NARCOTIC ) AND 
("Opiate Substitution Treatment"[Mesh] OR MAT OR medication-assisted treatment") AND 
(abstinence) 
("Analgesics, Opioid"[Mesh] OR OPIOID OR OPIOIDS OR OPIATE OR NARCOTIC ) AND 
("Opiate Substitution Treatment"[Mesh] OR MAT OR medication-assisted treatment") AND 
(retention) 
The queries used to investigate the effectiveness of contingency management included: 
("Analgesics, Opioid"[Mesh] OR OPIOID OR OPIOIDS OR OPIATE OR NARCOTIC ) AND 
"contingency management" AND systematic[subset]  
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("Analgesics, Opioid"[Mesh] OR OPIOID OR OPIOIDS OR OPIATE OR NARCOTIC ) AND 
"contingency management" AND theory OR theoretical OR framework OR Self Care OR self-
care 
Multiple combinations of the keywords “contingency management”, “opioid”, “opiate”, 
“abuse”, “substance abuse”, and “medication-assisted treatment” were used in CINAHL with 
modifiers such as “AND” or “OR”, to find relevant literature. In total, these search queries 
returned 323 relevant articles, and the search command “AND systematic [subset]” was 
instrumental for assessing systematic reviews of the subject. The search was limited to articles in 
the English language and published after December 31st, 2006. This time frame was chosen to 
eliminate findings that did not follow current MAT guidelines, and to reduce the total number of 
articles to a manageable number for review. Further, articles that did not focus on MAT for 
opioid use disorder or included an adolescent patient population were not included in the 
literature review. Ultimately, 11 articles, including seven systematic reviews, were retained. 
Review of Literature 
Background 
Opioid addiction, formally known as opioid use disorder per the Diagnostic and 
Statistical Manual of Mental Disorders (DSM 5; American Psychiatric Association [APA], 
2013), is diagnosed when an individual reports a problematic pattern of opioid use causing 
significant distress or impairment in daily functioning (APA, 2013). Two commonly used 
interventions include: (1) temporarily placing the patient in a controlled environment, where 
access to opioids is restricted while the patient is medically monitored during opioid withdrawal, 
or (2) MAT, which involves the utilization of prescribed, opioid-agonist medication to maintain 
the patient from experiencing opioid withdrawal while skills are developed to abstain from illicit 
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substance abuse. The goal of both methods is to support the patient in maintaining abstinence of 
opioid use. 
MAT is an effective, feasible intervention that encompasses the use of opioid-agonist 
medication, in combination with counseling and behavioral therapies, to provide patients with a 
holistic approach of treatment for substance abuse disorders (Substance Abuse and Mental 
Health Services Administration, 2019). Patients enrolled in MAT programs are expected to report 
daily to an outpatient facility for administration of opioid-agonist medication under close 
supervision while receiving periodic counseling services to develop and maintain sobriety from 
illicit substances. As compliance with MAT program standards are achieved throughout the 
course of treatment, clinical privileges such as take-home medications are granted to patients 
(Substance Abuse and Mental Health Services Administration, 2019).   
Contingency management is a form of behavioral therapy in which patients are rewarded 
for positive behavioral changes (Benishek et al., 2014). Targeted positive behavioral changes 
may include daily attendance for monitored dosing, participation in group counseling sessions, or 
achievement of abstinence from illicit substances. Through contingency management, patients 
are reinforced for positive behaviors, with the goal of motivating the patient to continue the 
positive behavior and achieve positive treatment outcomes (Center for Substance Abuse 
Treatment, 2005). The rewards utilized with contingency management are diverse and can be 
tailored by the healthcare provider. Common forms of rewards or prizes include monetary 
incentives, i.e. movie vouchers drawn from a prize bowl or vouchers for a day of free medical 
dosing (Benishek et al., 2014). Other incentives may include exclusive clinical privileges, such 
as priority dosing after positive behavior has been demonstrated by the patient. 
 
5 
Evidence Supporting Clinical Problem 
Study characteristics. The five articles within the literature review supporting the 
clinical problem included a systematic review focusing on MAT with methadone and its 
effectiveness in reduction of illicit opioid abuse and patient retention (Fullerton et al., 2014), a 
systematic review on medication and behavioral therapies associated with MAT for the treatment 
of opioid dependence (Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016), a RCT 
reviewing implementation of a disease management program and its effects on patient 
compliance and relapse to opioid abuse with MAT (Tkacz, Severt, Cacciola, & Ruetsch, 2012), a 
systematic review and random-effects meta-analysis assessing the efficacy of contingency 
management to reduce illicit substance abuse with opioid addiction treatment (Ainscough, 
McNeil, Strang, Calder, & Brose, 2017), and a secondary analysis of longitudinal data from two 
RCTs enrolled in MAT with hepatitis care coordination (Dhingra et al., 2015). All five scholarly 
works were published during or after December 2006; however, multiple articles included with 
the systematic reviews and meta-analyses originated prior to 2006 (Timko et al., 2016; 
Ainscough et al., 2017; Fullerton et al., 2014). The majority of literature was published in the 
United States, albeit multiple studies included in the systematic reviews were completed in China 
and some in locations not identified (Fullerton et al., 2014; Timko et al., 2016). Although these 
articles focused on substance abuse treatment with MAT among a diverse range of settings using 
varying forms of medication, including buprenorphine, buprenorphine-naloxone, and methadone, 
each study included in the unique pieces of literature derived outcome data from MAT designs 
using opiate substitution therapy treatment. 
Sample characteristics. In total, there were more than 4,000 subjects participating in the 
studies, with a sample of 703 patients used for one primary analysis alone (Tkacz et al.,2012).  
Where stated, the patient population was above 18-years-old (Timko et al. 2016; Dhingra et al. 
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2015; Tkacz et al., 2016) with an average patient age of 45.4 years-old with a standard deviation 
of 9.8 years (Dhingra et al. 2015) and 32.65 years-old with a standard deviation of 10.6 years 
(Tkacz et al., 2016). Thirty-two percent of the sample was female in the longitudinal study of 
RCTs (Dhingra et al. (2015). Gender demographics were lacking in the majority of the studies 
(Fullerton et al., 2014; Ainscough et al., 2017; Timko et al., 2016; Tkacz et al., 2016). Study 
settings included outpatient opiate treatment facilities, combined substance abuse and 
community health programs, and other outpatient facilities where opioid-substitution 
pharmacotherapy was administered. 
Results and outcomes. The evidence supports that achievement of patient abstinence and 
maintenance of high patient retention remains a serious clinical concern among MAT programs. 
A systematic review focused on patient retention among 55 RCTs observed a retention rate of 
72% after one month of treatment, retention rates as low as 19% after three months of treatment, 
and retention rates as low as 3% after 4 months of treatment (Timko et al., 2016). Two systematic 
reviews studying the effects of contingency management interventions with MAT demonstrated a 
high prevalence of poor patient outcomes for patients being treated for opioid use disorder with 
MAT (Ainscough et al., 2017; Fullerton et al., 2014). Although Ainscough et al. (2017) reviewed 
22 studies and suggested that contingency management is effective in reducing drug use in 
opioid addiction treatment, some studies reported a mean abstinence duration of just 4.8 days. 
Similarly, although Fullerton et al. (2014) reviewed 24 studies and provided a high level of 
evidence for the positive impact of MAT in improving patient retention and reducing illicit 
opioid abuse when compared to other forms of substance abuse treatment, one of the reviewed 
RCTs demonstrated only a 53% reduction of substance abuse after 160 days of treatment and 
another resulted in substance abuse rates above 40% for their patient sample. These results were 
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found across MAT programs of varying designs and forms of utilized medications in conjunction 
with behavioral interventions such as contingency management or cognitive behavioral therapy 
designed to improve retention and outcomes (Timko et al., 2016; Ainscough et al., 2017; 
Fullerton et al., 2014).  
 Approximately 180 patients comprised the sample for two RCTs focused on MAT with 
concurrent hepatitis treatment and abstinent rates. Without evidence of illicit drug use at 
baseline, only 108 patients continued to provide negative drug screens later in the course of 
treatment, indicating that there was a decrease in abstinence throughout the course of MAT 
(Dhingra et al., 2015). Further, the results of these trials demonstrated that 29.5% of the patient 
sample continued with illicit drug use during MAT across four assessment points during a one-
year period per patient self-report, and only 27% of the total sample endorsed abstinence across 
the span of the year (Dhingra et al., 2015). Another RCT with a sample of 703 subjects in the 
primary analysis reported that that 20% (n = 142) endorsed opioid use within the second or third 
month of MAT, with 62% of these patients relapsing with the use of pharmaceutical opioids 
(Tkacz et al., 2012). Secondary analysis of this study found compliance with program standards 
(i.e. reporting to the clinic for daily dosing), contributed significantly to continued illicit drug use 
and risk of relapse (Tkacz et al., 2012). The reviewed RCTs shared similar settings, as both 
samples were observed in MAT programs occurring in outpatient settings where daily dosing 
was expected and opioid agonist medications were administered (Tkacz et al., 2012; Dhingra et 
al., 2015). 
 The quality of this evidence is strong with a study quality of Level 1 and an ‘A’ strength 
of recommendation according to Ebell et al. (2004). The studies have multiple strengths, 
including large samples of articles to establish a significant effect and the utilization of 
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biochemically verified markers to confirm outcome measures (Fullerton et al., 2014; Ainscough 
et al., 2017; Timko et al., 2016). Further, there was a minimal risk of bias within the studies, and 
they shared similar results. Although different designs of MAT were used among the studies, the 
results are generalizable to most patient populations enrolled into MAT due to the large number 
of studies utilizing similar outcome measures. A common weakness among the systematic 
reviews was a failure to provide specific sample sizes of the studies the authors reviewed 
(Fullerton et al., 2014; Ainscough et al., 2017; Timko et al., 2016). 
Evidence Supporting the Intervention: Contingency Management 
Study characteristics. Six articles were included with a focus on the implementation of 
contingency management and its effect on patient outcomes in MAT. Included were  a systematic 
review of literature discussing contingency management and its role in reducing the prevalence 
of substance abuse in MAT (Davis et al., 2016), a systematic review and meta-analysis that 
reviewed randomized controlled trials to assess the efficacy of contingency management versus 
treatment-as-usual conditions (Benishek et al., 2014), a systematic review including a random-
effects meta-analysis of 22 articles assessing the potential of contingency management in 
reduction of illicit substance abuse during opiate addiction treatment (Ainscough et al., 2017), a 
systematic review of 27 articles exploring a multitude of psychosocial and behavioral therapies 
that may be implemented with MAT to increase abstinence among patient populations in a 
variety of treatment settings (Dugosh et al., 2016), and, two randomized controlled trials that 
compared the effects of contingency management versus treatment-as-usual conditions of 
methadone-maintained patients (Ginley, Rash, Olmstead, & Petry, 2017; Hser et al., 2011). These 
studies were published during or after 2011; however, a portion of the reviewed literature in the 
systematic reviews originated prior to 2011. The studies were conducted in the United States and 
China, although there were undeclared locations within articles of the systemic reviews 
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(Ainscough et al., 2017; Benishek et al., 2014; Dugosh et al., 2016; Davis et al., 2016). All 
studies focused on contingency management and its incorporation into MAT with evaluation of 
its impact on patient abstinence and retention.  
Sample characteristics. More than 3,000 subjects were included in the randomized 
controlled trials and systematic reviews with associated meta-analyses. Most studies failed to 
report sample sizes (Davis et al., 2016; Dugosh et al., 206; Benishek et al, 2014; Ainscough et 
al., 2017; Lussier et al., 2006). Study populations consisted of adults above the age of 18 years 
old who were receiving substance abuse treatment for opioid use disorder with mediation-
assisted treatment utilizing opioid-substitution therapy (Ginley et al., 2017; Hser et al., 2011). 
Age and gender demographics were not provided by the studies of Ainscough et al. (2017), 
Davis et al. (2016), and Dugosh et al. (2016), though the average age in the RCTs conducted by 
Ginley et al. (2017) was 38.4 years-old with 41.4 % of the patient sample being male. The RCT 
conducted in China by Hser et al. (2011) reported a mean subject age of 38 years-old with 76.2% 
of the sample being male. Study settings included outpatient methadone clinics, intensive 
outpatient programs, drop-in centers providing substance abuse treatment, and other forms of 
outpatient facilities. 
Results and outcomes. The evidence supported an association between the incorporation 
of contingency management into MAT and positive patient outcomes, including increased 
abstinence from illicit substance and retention through the course of treatment for opioid use 
disorder. The results of these three systematic reviews suggest that contingency management 
interventions may produce significant, medium-to-large effects for diverse patient populations 
undergoing treatment for substance abuse disorders across different settings and MAT modalitGF            
ies (Davis et al., 2016; Dugosh et al., 2016; Benishek et al., 2014). A systematic review by Davis 
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et al. (2016) comprised of 69 studies focused on contingency management reported a significant 
treatment effect for abstinence of illicit substance abuse during MAT with a pooled effect value 
of d=0.6 (95% CI: 0.41-0.92). Similarly, a systematic review conducted by Benishek et al. (2014) 
of 19 RCTs, which included a meta-analysis of randomized controlled trials to assess the efficacy 
of contingency management in reduction of substance abuse in comparison to treatment-as-usual 
conditions, resulted in a random-effects weighted mean effect size of d = 0.46, (P < 0.001, 95%; 
CI = 0.37, 0.54). Further, this study found that the weighted mean effect size for the effect of the 
contingency management intervention upon the dependent variable (percentage of biochemically 
verified negative drug screens among patients) was d =0.46 with a p value of <0.001 at a 
confidence interval of 95% (Benishek et al., 2014). A systematic review consisting of 27 articles 
reported that contingency management participants were observed to have higher rates of MAT 
completion (p<0.05), provided more morphine-free urine samples (p<0.001), and attended more 
days of treatment (p<0.01) when compared to patients who were not receiving contingency 
management (Dugosh et al., 2016). The evidence supports multiple forms of contingency 
management were effective in promoting positive patient outcomes across a variety of MAT 
designs being delivered in outpatient settings. The results can be considered generalizable to the 
general adult patient population receiving MAT (Davis et al., 2016; Dugosh et al., 2016; 
Benishek et al., 2014). 
Two randomized controlled trials yielded results congruent with the findings of the 
systematic reviews (Hser et al., 2011; Ginley et al., 2017). A pair of randomized controlled trials 
completed in China with a patient sample of 319 patients observed a retention rate of 81% across 
12 weeks of MAT for patients receiving contingency management, compared to a retention rate 
of 67% who did not (Hser et al., 2011). Another set of randomized controlled trials in the United 
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States consisting of 323 subjects found that the mean longest duration of abstinence was higher 
for patients receiving contingency management with values reported at M = 4.22 weeks (SD = 
0.30) (p<0.002) versus M = 1.89 weeks (SD =0.34) (p<0.001) for the control group (Ginley et 
al., 2017). In addition, the proportion of negative drug screens was higher for the intervention 
group at M = 49.8 % (SD = 2.7) (p<0.001) versus the control group at M = 28% (SD =3.0) 
(p<0.001). Both sets of these RCTs took place in similar settings consisting of outpatient opioid 
treatment facilities where adult patients were administered opioid-agonist medications and 
received regular counseling during treatment (Hser et al., 2011; Ginley et al., 2017). 
In contrast with other articles, one systemic review and associated meta-analyses of 22 
studies found that contingency management was not helpful with promoting abstinence from 
illicit opioid use during MAT (Ainscough et al., 2017). However, the intervention was associated 
trials of patients receiving contingency management while undergoing opioid addiction treatment 
with opioid substitution therapy, the random effects meta-analyses for longest duration of 
abstinence from all illicit substances produced a pooled effect size of d=0.57 (95% CI: 0.42-
0.72), with contingency management performing significantly better than treatment-as-usual 
conditions. Although the findings of this review and associated results from the meta-analysis 
appear to be outliers from general findings of other evidence-based research, they indicate that 
there is a need for further research in how contingency management is associated with abstinence 
in specific type of illicit substances. 
A common limitation among this review of literature was the failure to differentiate 
abstinence among specific drug types (Ainscough et al., 2017; Benishek et al., 2014; Dugosh et 
al., 2016; Davis et al., 2016). The majority of authors did not explicitly state whether positive 
biological indicators of substance abuse were indicative of illicit opioid use or the use of another 
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illicit substance such as cocaine; therefore, there is limited research that assesses the effect of 
contingency management upon the reduction of abuse for specific drug types. Rather, the 
majority of evidence-based research assesses the moderating effects of contingency management 
on polysubstance drug use. Further, the systematic reviews in this portion of the review of 
literature did not provide many characteristics of their reviewed patient samples, thus there may 
be limited generalizability for specific sub-populations of patients (Ainscough et al., 2017; 
Benishek et al., 2014; Dugosh et al., 2016; Davis et al., 2016). There was also a general lack of 
discussion for compounding variables that may have impacted the observed outcome variables. 
Factors such as polysubstance dependence or socioeconomic status were not discussed in the 
literature, and these variables may play a significant role in the observed results of their studies. 
The quality of this evidence is strong with a study quality of Level 1 and an ‘A’ strength 
of recommendation according to Ebell et al. (2004). The included articles consist of the highest 
level of evidence available and contain multiple strengths, including systematic reviews with 
large article samples to establish a significant effect, large patient samples with varying 
demographics and treatment settings to establish generalizability, and the inclusion of meta-
analyses that provide quantitative support of contingency management’s efficacy as an 
intervention to promote positive patient outcomes (Davis et al., 2016; Benishek et al., 2014; 
Dugosh et al., 2016). In addition, patient outcome measures were reported with the utilization of 
biochemically verified markers to confirm outcome measures in all articles. These results are 
likely to be more valid, as it is strictly biochemically confirmed data. Although there were 
different designs of MAT included among the literature, the results are generalizable to most 
patient populations enrolled into MAT due to similar outcome measures stemming from the 
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many separate studies (Ainscough et al., 2017; Hser et al., 2011; Ginley et al., 2017; Davis et al., 
2016; Benishek et al., 2014; Dugosh et al., 2016).  
Summary  
This review of literature and synthesis of evidence-based practice confirms there is a 
serious clinical problem experienced within substance abuse treatment with MAT. High rates of 
illicit substance abuse and poor patient retention continue throughout MAT, despite the use of 
varying forms of opioid substitution therapy and traditional psychosocial interventions utilized to 
promote positive patient outcomes. However, there is also evidence to suggest that contingency 
management may be incorporated into MAT to improve patient outcomes. Contingency 
management may mitigate negative treatment outcomes if it is implemented in an effective 
manner with appropriate delivery by clinical staff. When critical moderators contingent for the 
successful implementation of contingency management are met by clinical staff, results from this 
review of literature suggest the intervention may improve patient outcomes with higher rates of 
achieved abstinence and patient retention within the induction phase of treatment. 
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CHAPTER 2: CONCEPTUAL FRAMEWORK 
 The Model for Improvement (MFI), a conceptual framework developed by the Institute 
for Healthcare Improvement (IHI), was used to guide implementation of this DNP Project 
(Langley, Moen, Nolan, Norman, & Provost, 2009). This evidence-based conceptual framework 
is designed to accelerate improvement through the guidance of purposeful action and has been 
used by numerous healthcare organizations across the globe to drive quality improvement 
projects and promote positive patient outcomes (IHI, 2020). The model may be used as a guide 
to identify aims, measures, and idealized changes before a quality improvement process is 
implemented. More importantly, the MFI includes an algorithm for achieving the identified aim 
through a sequential testing of changes known as plan-do-study-act cycles (PDSA). The 
components of a PDSA cycle include development of the plan to test the change (plan), 
execution of the change (do), assessment of results of the change (study), and modifications to 
further improve upon the outcomes of the change (act). The Model for Improvement served as an 
essential guide by providing a sound, evidence-based method for implementation of a quality 
improvement practice change through a dynamic process of action and learning (Langley, Moen, 
Nolan, Norman, & Provost, 2009). 
 The PDSA cycles encourage an approach that tests interventions in a manner allowing for 
rapid assessment, providing opportunities to create modifications to improve upon the 
intervention while minimizing negative patient outcomes and promoting the likelihood of 
achieving the identified aims. The assessment of results at the conclusion of each cycle measures 
the impact of the intervention and its process towards the outcomes of interest. The measurement 
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of the data within each PDSA cycle, over periods of time, allows researchers to understand 
variations within the healthcare system and become aware of unforeseen variables influencing 
the success if the intervention and its progress toward positive outcomes (Speroff & O’Connor, 
2004). Aligned with the teachings of the scientific method, the documentation at the terminal 
stage of each PDSA cycle is critically important to provide support for the quality of the 
intervention. It is also critical for the capture of knowledge and the generalizability of the results 
from the intervention (Boaden, Harvey, Moxham, & Proudlove, 2008).  
The evidence supports the the Model for Improvement and its encompassed PDSA cycles 
are associated with successful quality improvement practice changes that have led to improved 
delivery of healthcare and positive patient outcomes. Studies have consistently demonstrated the 
value of the MFI and its role in successfully implementing a practice change.   
Project Design 
 The DNP project was a quality improvement practice change. Practice change seeks to 
improve quality and safety of patient outcomes through integration of evidence-based research 
and clinical practice. An important criterion for successful practice change includes sustainable 
improvements that can be maintained by the healthcare organization (Titler, 2008). The primary 
aim of this practice change was the integration of contingency management within treatment-as-
usual conditions of MAT that resulted in optimal rates of staff adherence to the protocol. The 
secondary aim was to improve abstinence rates and clinical retention within the first nine weeks 
of treatment. The practice change was guided by the MFI, using three plan-do-study-act cycles to 
allow for real-time evaluation and improvements during implementation of the practice change 
(Speroff & O’Connor, 2004).
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CHAPTER 3: METHODS 
Contingency management was implemented within treatment-as-usual conditions of 
MAT using the MFI to achieve high staff compliance and improve upon abstinence rates and 
clinical retention within the induction phase of treatment (i.e. first nine weeks of treatment). The 
contingency management protocol used positive reinforcement including verbal affirmation, a 
framed certificate presented to the patient, and an invitation to a celebratory breakfast hosted by 
the facility in honor of all patients who had reached the therapeutic goal of abstinence from 
substance use during the first induction phase. Positive reinforcement was earned when the 
patient’s first biological indicator of abstinence (urine drug screen) was achieved within the first 
nine weeks of treatment. The primary outcome was a high rate of staff adherence to the 
contingency management protocol. The secondary outcomes were improved abstinence rates, 
increased retention within treatment, and increased rates of maintained abstinence for patients 
who had received contingency management. 
Setting and Participants 
 The setting was an outpatient substance abuse facility specializing in the delivery of MAT 
for an adult population with opioid addiction in the Southeastern United States. The stakeholders 
and participants included: a director of n2ursing who discussed the contingency management 
protocol during the intake process for all eligible patients, a program nurse who identified 
patients who achieved their first negative drug screen, certified substance abuse counselors and 
licensed clinical addiction specialists who delivered the intervention, and a clinical director and 
administrative nurse who conducted retrospective chart reviews to assess compliance with the 
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intervention (Table 1). All participants in the practice change process received education about 
the intervention at a mandatory staff meeting prior to the implementation of the first PDSA cycle. 
These participants worked together to ensure a successful implementation of the intervention 
throughout each PDSA cycle. 
Patients 18 years of age and older who began treatment between June 22, 2020 and 
October 7, 2020, were eligible to receive the contingency management, based upon the 
achievement of their first negative drug screen. 
Ethics and Human Subjects Review 
 The proposal was submitted to the UNC Institutional Review Board and resulted in a   
determination that Study # 20-1317, research or research-like activity, did not require IRB 
approval. 
 
Process for Implementation  
  A mandatory meeting was scheduled one week before the initiation of the first PDSA 
cycle to prepare all clinical staff participants to implement the contingency management 
protocol. The Project Lead discussed the established protocol, the underlying theory behind 
contingency management, the aims of the proposed DNP project, and the MFI conceptual 
framework. The roles and expectations of each member involved in the implementation of the 
project was discussed at the meeting, with follow-up discussion to address questions as they 
arose. The participants were provided a bulleted handout-overview of the same information 
provided at the meeting. Each participant signed and dated two copies, one returned to the 
Project Lead and one they kept for their own records. The participant’s signature indicated 





Table 1. Participant Roles 
Participant Roles   
 Responsibility Activity 
Program Lead Supervise the implementation 
process, support clinical staff  
Discuss DNP project and 
contingency management 
protocol during staff meeting, 
answer questions, assess 
aggregate data, conduct  
semi-formal staff interviews, 
Nursing director Provide education to new 
patients  
Discuss contingency 
management protocol during 
intake process 
Program Nurse Identify patient eligible for 
positive reinforcement after 
achieving targeted therapeutic 
goal 
Assess drug screen reports of 
new intakes and flag patient 
profiles to see assigned 
counselor if negative drug 
screen is found 
CSAC Deliver positive 
reinforcement to patient at the 
appropriate time 
Meet with flagged patient 
within 24 hours of achieved 
negative drug screen and 
deliver positive reinforcement 
LCAS Deliver positive 
reinforcement to patient at the 
appropriate time 
Meet with flagged patient 
within 24 hours of achieved 
negative drug screen and 
deliver positive reinforcement 
Clinical Director Conduct retrospective chart 
review to assess whether the 
contingency management 
protocol was explained 
during intake process 
Complete weekly 
retrospective chart review and 
provide Project Lead with 
unidentifiable, aggregate 
data.  
Administrative Nurse Conduct retrospective chart 
review to assess whether 
positive reinforcement was 
delivered appropriately 
Complete weekly 
retrospective chart review and 







Three PDSA cycles were implemented, with each cycle lasting 21 days (Table 2). At the 
conclusion of each PDSA cycle, a debriefing with the clinical staff-participants involved in that 
cycle was conducted by the Project Lead (Table 3). Efficacy of the established protocol, any 
barriers that arose, and possible changes in the implementation process were discussed. The 
debriefing questions were: Were you able to comply with the protocol as it is written? Did you 
identify any barriers that prevented implementation or made it more difficult? Are there any 
changes that need to occur in the protocol?   
PDSA cycle 1 began the practice change and included weeks 1 through 3 of the 
implementation period, beginning on 06/22/2020 and concluding on 07/10/2020. The director of 
nursing, program nurse, administrative nurse, clinical director, and two licensed LCASs 
participated in the intervention during cycle 1. New patients admitted during PDSA cycle 1 were 
assigned to one of the two licensed LCASs, with the expectation that the assigned LCAS would 
deliver the positive reinforcement if abstinence were achieved. Positive reinforcement included 
verbal affirmation, a framed certificate, and an invitation to a breakfast held to celebrate their 
achievement. During the intake process, the contingency management protocol was explained by 
the director of nursing to each new patient. The director of nursing ensured that patients 
understood the contingencies being used as positive reinforcement to be earned after abstinence 
was achieved as evidenced by a negative drug screen.  Any questions from patients were 
answered at that time.   
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Table 2. PDSA Implementation Schedule  
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PDSA # 2  
Begins 
PDSA # 1  
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28 29 30 31  
Color Corresponding Cycle 
Green PDSA # 1 
Blue PDSA # 2 
Orange PDSA # 3 
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Table 3. Debrief Questions 
Debrief Questions   
 End of PDSA Cycle 1 & 2 Post Implementation 
Question 1 Were you able to comply with 
the protocol as it is written? 
Were you able to consistently 
achieve compliance with the 
protocol by the end of the 
implementation period? 
Question 2 Did you identify any barriers 
that prevented 
implementation or made it 
more difficult? 
What can be improved upon 
the protocol to facilitate 
compliance? 
Question 3 Are there any changes that 
need to occur in the protocol? 
 
Did your patients respond 




Throughout the PDSA cycles, patients completed weekly drug screens as mandated by 
treatment-as-usual conditions of the clinic. These drug screens were reviewed by the program 
nurse daily; if a patient enrolled in the contingency management protocol achieved a negative 
drug screen, his or her profile was immediately flagged to see a licensed counselor for the 
delivery of the positive reinforcement the following day. For PDSA cycle 1, this task was the 
responsibility of one of the two fully licensed LCASs at the facility. Compliance with the 
contingency management protocol required the patient’s chart must be flagged the day the 
negative drug screen was reviewed by the program nurse, and then promptly seen by their 
assigned LCAS for receipt of the positive reinforcement within 24 hours. If the patient had 
already reported to the clinic that day, the delivery of the intervention was expected the following 
day, within 24 hours of receiving the drug screen. Compliance was tracked in the facility’s 
electronic medical record platform. At the completion of PDSA cycle 1, a debriefing with all the 
clinical staff-participants involved in that cycle was conducted to assess efficacy of the process, 
discuss any barriers that arose, and identify needed changes.  
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PDSA cycle 2 began after the debriefing and included weeks four through six of the 
implementation period. It began on 07/13/2020 and concluded on 07/31/2020. Clinical staff 
participants in PDSA cycle 2 increased from six to nine, as three provisionally licensed LCASs 
joined the two fully licensed LCASs who participated in PDSA cycle 1 and were allowed to 
deliver positive reinforcement. Continuing clinical staff included the director of nursing, who 
explained the contingency management protocol during the intake process for all newly enrolled 
patients; the program nurse, who continued to identify patients who achieved their first negative 
drug screen and flagged the charts of those patients to report to their counselors to receive the 
positive reinforcement; and the clinical director and administrative nurse who continued to 
collect aggregate patient data. At the conclusion of PDSA cycle 2, the Project Lead conducted a 
debriefing with the nine staff participants using the same questions from cycle 1. 
PDSA cycle 3 continued for the final 21 days, including weeks seven through nine of the 
implementation period. It began on 08/03/2020 and concluded on 08/21/2020. This cycle 
allowed all CSACs to deliver positive reinforcement, in addition to the LCASs who did so in the 
previous cycles. Clinical staff participants increased from nine to 13 in the final cycle, with all 
roles remaining the same. The roles of continuing participants were unchanged in this cycle, and 
CSACs or LCASs delivered the positive reinforcement within 24 hours of the identified negative 
drug screen. It is important to note, during PDSA cycle 3, that the incorporation of newly 
admitted patients ended two weeks before the conclusion of the implementation period to ensure 
enough time was given to provide a negative drug screen (Table 2). Newly admitted patients 
after week seven could not be enrolled into the practice change because there was not sufficient 
time to achieve abstinence and receive the intervention before the conclusion of the 
implementation period. A final-post implementation debriefing was conducted with all clinical 
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staff participants at the conclusion of PDSA cycle 3 (Table 3). The questions were: Were you 
able to consistently achieve compliance with the protocol by the end of the implementation 
period? What can be improved upon the protocol to facilitate compliance? Did your patients 
respond positively to the contingency management protocol? 
Data Collection 
 The Model for Improvement emphasizes the importance of measurement during 
implementation of change, as measures inform the stakeholders whether the intervention is being 
delivered appropriately or leading to a significant improvement (IHI, 2020). The results of this 
project consisted of quantitative and qualitative data. The primary outcome of the project, the 
adherence to the contingency management protocol, was accomplished through review of 
aggregate data collected from retrospective chart reviews conducted by the clinical director and 
administrative nurse at the conclusion of each PDSA cycle. 
  The clinical director assessed clinical case notes made by the director of nursing to 
determine whether the contingency management protocol had been explained on the day of 
intake. Aggregate data was presented to the Project Lead, who determined the rate of protocol 
compliance across the three PDSA cycles and the overall implementation period.  
The administrative nurse reviewed drug screen records of all patients enrolled in the 
contingency management protocol to determine whether a negative drug screen was correctly 
identified and if the patient’s chart was subsequently flagged for the patient to see their 
counselor. The administrative nurse also reviewed counselor case notes to assess if the 
contingency management protocol was delivered within 24 hours of the identified negative drug 
screen. All data was provided to the Project Lead who analyzed compliance rates for both the 
program nurse assigned to review drug screens, and the counselor responsible for delivering the 
positive reinforcement within the allotted 24 hours. Recorded aggregate data for each PDSA 
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cycle was saved and analyzed in Excel (Version 16.42, 2020). Data from end of cycle debriefings 
and post-implementation briefing was documented in the form of written notes by the Project 
Lead during each respective debriefing session. 
Data Analysis and Evaluation 
 Aggregate data was analyzed at the conclusion of each PDSA cycle to assess progress 
towards the identified project outcomes. This data, in the form of counts and ratios, allowed the 
Project Lead to determine the rate at which the contingency management protocol compliance 
had been achieved. Rates of achieved abstinence, maintained abstinence, and patient retention 
were calculated for each PDSA cycle and for the overall implementation period. Successful 
compliance was defined as 1) the intervention was properly explained to the patient during the 
intake process, and 2) the contingency management intervention was delivered 24-hours within 
achievement of the first negative drug screen.  
Qualitative data was collected and documented in the form of written notes during the 
debriefings with all clinical staff participants at the conclusion of each cycle. Content analysis 
was utilized to analyze this data (Colorado State University, 2020). This data gave voice to their 
thoughts and concerns regarding the intervention, allowing for evaluation of barriers to the 
implementation process. The documented notes were reviewed for themes by the DNP Project 
Lead and the DNP Project Chair. The themes were discussed to determine congruence between 
both reviewers.  
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CHAPTER 4: RESULTS 
 During the implementation period of nine weeks, a total of 42 patients were enrolled in 
the contingency management protocol and had the opportunity to receive the contingency 
management intervention, contingent upon providing a negative drug screen which demonstrated 
abstinence from illicit drug use within the first 28 days of treatment. Demographic data of the 
clinical staff participants is presented in Table 4.  
 
Table 4. Demographics 
 
 
Staff adherence to the intervention protocol (explanation of the protocol during intake, 
and appropriate delivery of contingency management within 24 hours of receiving a negative 
drug screen) was variable across the three PDSA cycles. Specific patient outcomes observed 
included retention within treatment, achieved abstinence within 28 days of the intake date, and 
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maintained abstinence after initial abstinence had been demonstrated. The practice change was 
considered positive by both clinical staff and patients. 
Compliance 
The average rate of compliance for the explanation of the contingency management 
protocol during the intake process was 92.8%. Chart review of nursing notes and data collection 
by the clinical director demonstrated the variability of staff adherence during each PDSA cycle, 
resulting in less than 100% compliance by clinical staff participants for the intervention. During 
PDSA cycle 1, the director of nursing achieved a compliance rate of 100% for explaining the 
contingency management protocol to patients during the intake process. During PDSA cycle 2, 
compliance in this category decreased to 57% (Figure 1). The barrier to compliance in PDSA 
cycle 2 was identified to be a lack of education for the administrative nurse to explain 
contingency management to new patients on days when the director of nursing was absent. After 
the administrative nurse was educated, and the protocol revised to update the expectations for 
this role, compliance in this category returned to 100% in PDSA cycle 3. 
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Figure 1. Staff Compliance During Intake Process 
 
The average rate of compliance for delivering contingency management within 24 hours 
after receiving a negative drug screen was 88%. Comprehensive review of drug screen records 
and counselor case notes by the administrative nurse revealed compliance in this domain 
improved consistently across the three PDSA cycles. The compliance rate of this component of 
the protocol during PDSA cycle 1 was 75%. The barrier to compliance was an issue related to the 
LCAS being unprepared for delivery of the contingency management. The protocol was revised 
to require the program nurse to notify the counselor directly, in addition to flagging the patient, 
on the day a negative drug screen was received. During PDSA cycle 2 compliance increased to 
88%. The second barrier occurred with absences among counseling staff that led to the delivery 
of positive reinforcement being delayed beyond 24 hours of the identified negative drug screen. 
To resolve this issue, the protocol was revised to include expectations for the clinical director to 
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deliver positive reinforcement in the place of an LCAS or CSAC if they were to be absent, 
resulting in 100% compliance achieved for PDSA cycle 3 (Figure 2).  
 
Figure 2. Staff Compliance with Administering Positive Reinforcement 
 
Patient Outcomes 
 A total of 42 patients were involved in the three PDSA cycles, completing the intake 
process and enrolled in the contingency management protocol. Among all patients enrolled 
throughout the nine-week implementation process, 43% (n=18) achieved abstinence within 28 
days of their date of intake and received contingency management. Of the patients who received 
the intervention, 77% (n=14) maintained abstinence throughout the entire implementation period 
and 89% (n=16) remained in treatment for all 28 days of beginning MAT. Accounting for all 
patients enrolled in the contingency management protocol, regardless of whether they received 
the intervention, 83% (n=35) remained in treatment for their first 28 days of receiving MAT. 
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These results may be compared to the previous patient cohort who began treatment May 25, 
2020 through June 21, 2020; the 28-day period prior to initiation of the contingency management 
practice change. This cohort included a total of 15 patients, of these patients, 41% remained in 
treatment and 24% achieved abstinence within 28 days of their date of intake.  
 
Figure 3. Patient Outcomes  
 
 Patient outcomes specific to each PDSA cycle remained variable across the 
implementation period as indicated in Figure 3. The first PDSA cycle included weeks one - three 
(06/22/2020 - 07/10/2020) with a cohort of 22 patients completing the intake process and 
enrolled in the contingency management protocol. Within 28 days of their date of intake, 50% 
(n=11) of patients in the first cohort were able to achieve abstinence from illicit drug use and 
received contingency management (Figure 3). Of the patients who received the intervention, 
100% (n=22) were still in treatment within the first 28 days of beginning MAT and 73% (n=16) 
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were able to maintain abstinence by consistently providing weekly drug screens throughout the 
remainder of the implementation period. Accounting for all patients in the first cohort, including 
those who did not achieve abstinence and therefore did not receive contingency management, 
91% (n=20) of patients were still in treatment within 28 days of their intake (Figure 3).  
PDSA cycle 2 included weeks four through six (07/13/2020 - 07/31/2020) a cohort of 
seven patients completing the intake process and enrolled in the contingency management 
protocol. Of this cohort, 29% (n=2) achieved abstinence within 28 days of their date of intake 
and received the contingency management (Figure 3). Within the second cohort, 50% (n=1) of 
patients who received contingency management were able to maintain abstinence for the 
remainder of the implementation period and 100% (n=7) of all patients in the second cohort 
remained in treatment for the first 28 days after intake (Figure 3).  
The third and final PDSA cycle included weeks seven through nine (08/03/2020 - 
08/21/2020) with a cohort of 13 patients completing the intake process and enrolled in the 
contingency management protocol. Of this cohort, 38% (n=5) achieved abstinence within 28 
days of their date of intake and received the contingency management intervention (Figure 3). Of 
patients who received the intervention, 100% (n=5) were able to maintain abstinence for the 
remainder of the implementation period, and 80% (n=4) remained in treatment for the first 28 
days after intake (Figure 3). Accounting for all patients within the cohort, including those who 
did not achieve abstinence, 62% (n=2) remained in treatment for the first 28 days of receiving 
MAT (Figure 3).  
PDSA Cycle and Post-Implementation Debriefings 
Clinical staff reception to the intervention was positive. At the conclusion PDSA cycles 1 
and 2, all staff participants involved in the contingency management protocol participated in a 
debriefing. Staff participants discussed their personal adherence to the protocol as written, 
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identified barriers that made delivery of contingency management difficult, and made 
recommendations to improve the protocol for intervention efficacy and compliance. A post-
implementation debriefing was conducted with three different questions guiding the evaluation 
of the overall practice change of contingency management within MAT. Notes were written 
during each debriefing to document all feedback from clinical staff participants. 
During clinical staff debriefings at the conclusion of PDSA cycle 1, all but one participant 
reported that they had no difficulty with maintaining compliance. One of the licensed LCAS who 
had failed to maintain proper adherence to the protocol stated that having the certificate prepared 
by the program nurse and it being delivered to the counselor before the scheduled intervention 
would facilitate compliance. No other barriers to compliance were identified, though one LCAS 
noted “the intervention itself took more time than expected because the patient became 
emotional when congratulated about her achievement.” When asked about changes that needed 
to occur in the protocol, several concerns were raised. The program nurse identified the need for 
designated back-up to assume responsibility for monitoring drug screens and flagging patients 
when the program nurse was absent, a LCAS suggested the certificate provided to the patient 
could be improved aesthetically by “delivering it in a frame”, and the licensed specialist who had 
failed to adhere to the protocol reiterated counselors should be “personally notified the day 
before contingency management is expected to be given in order to prepare for the intervention.”  
During staff debriefings at the conclusion of PDSA cycle 2, two staff participants 
discussed issues when asked if they were able to comply with the protocol as written. The 
administrative nurse explained that she was unaware of the expectation to deliver the 
contingency management explanation during the intake process when covering for absences of 
the director of nursing. As a result, three new patients (intakes) on 07/22 were not aware of the 
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contingency management protocol during their intake process. Additionally, a LCAS identified a 
back-up plan was needed with the LCAS was absent. No additional barriers were noted during 
this debriefing. Based on identification of these barriers to compliance, changes to the protocol 
included training nurses to assuming the responsibilities of the director of nursing during any 
absences, and designation of the clinical director to serve as a back-up when a LCAS was absent 
from the clinic. 
During the post-implementation debriefing, staff-participant feedback regarding 
compliance indicated there was no overt issue or barrier for maintaining adherence. One staff 
participant stated, “delivering the intervention was easy, as long as I was notified in time to 
prepare the materials and free my schedule to see the patient.” Several recommendations were 
offered when asked how the protocol could be improved to facilitate compliance. The program 
nurse said, “the clinical director should know if specific counselors began failing to deliver the 
positive reinforcement within the time frame.” Multiple participants stressed the inclusion of 
stronger incentives. A CSAC advised, “you should consider take-home medication to as an 
awarded privilege”, another recommended using “a physical ticket to the breakfast as opposed to 
a verbal invitation, because a ticket is tangible and material.” When asked how their patients 
responded to the contingency management intervention, responses were positive. The 
administrative nurse, who explained the intervention during intake during the absence of the 
director of nursing, reported “they appeared excited to hear about positive reinforcement and 
stated a desire to be clean.” LCASs and CSACs who delivered the intervention stated that many 
patients “had emotional responses and feelings of pride”, and some patients were “surprised that 
they were being recognized for the achievement, but very appreciative.” A CSAC discussed how 
a patient verbalized “feeling like a failure for many years, and this moment was very important 
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to me because I had finally accomplished something meaningful.” The clinical director noted 
that many of the patients who received contingency management “have remained sober since 
their first negative drug screen”; one patient’s response indicated an emotional reaction with the 
statement, “this is the first time that someone has been proud of me in years.” The program 
nurse, who did not have direct patient contact, reported “multiple patients who were not in the 
induction phase of treatment heard about the protocol and stated they would have liked to have 
been included.” Another CSAC said, “many of the patients on my caseload told me they wished 
they had something like contingency management when they were new patients.” 
Themes from Debriefings 
Staff-participant responses during each PDSA cycle debrief provided insight regarding 
efficacy of the protocol, barriers to maintaining compliance, and recommendations for changes 
in the protocol that would improve compliance. The post-implementation debriefing allowed 
staff-participants to discuss their overall experience with implementation of contingency 
management and whether or not they had been able to maintain compliance with the final 
protocol, discuss if recommendations for changes in the protocol had been effective, and discuss 
their patients’ responses to the intervention. The written documentation of the feedback was 
reviewed by the Project Lead and DNP Project Chair to discuss content and evaluate themes.  
Three themes were identified: staffing patterns, patient reactions, and staff reactions.  
Staffing patterns, the first theme, related to the critical, designated roles required to implement 
the contingency management and track compliance. The roles were designated by credential, 
which guided the type of interaction the staff-participant had with the patients. Staffing issues 
were mentioned frequently and proved to be the main barrier to optimal compliance to the 
contingency management protocol.  Problems arose with the lack of a back-up plan to ensure a 
specific task could be completed in the absence of the designated person. Staff-participants 
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quickly recognized the necessary actions required to eliminate the barriers and were able to 
implement the recommendations.  These actions were effective in removing the barriers. 
The second theme, patient reactions, encompassed emotional responses and verbal 
feedback from patients to any of the clinical staff participants throughout the implementation 
period. Both participating and non-participating patients expressed a positive reaction to 
contingency management. Direct quotes from the patients, discussed above, emphasized their 
strong positive reactions to the practice change, and reinforced the motivational influence of 
contingency management. Verbal affirmation was the strongest positive reinforcer, frequently 
eliciting an emotional response from those receiving the intervention. During their battle with 
opioid use disorder, and addiction in general, many had destroyed their relationships with friends 
and family. Upon achieving their first negative drug screen, and being verbally affirmed by their 
counselor, they felt pride and hope for recovery, emotions that had become foreign in the 
hopelessness they experienced before receiving contingency management. 
The third and final theme was related to staff reactions. This included clinical staff 
participants’ buy-in to the practice change and their responsiveness, both behaviorally and 
verbally, to the debriefings. The reactions to the contingency management protocol were 
consistently positive. Staff in the counselor-role discussed how delivery of the positive 
reinforcement “helped build rapport” between themselves and their patient, a critical component 
of any therapeutic relationship. They stated delivery of the positive reinforcers was “not difficult 
nor time consuming,” thereby facilitating optimal compliance. The solutions to previously 
identified barriers prepared the staff-participants for effective delivery of the intervention. All 
staff-participants expressed favorable views of contingency management, and from their 
perspective, believed patients earning the positive reinforcement also had a significant positive 
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emotional experience. Several staff noted all comments from patients were favorable, adding 
patients who were not involved in the implementation were discussing the contingency 
management and wishing they could have been a part of it. 
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CHAPTER 5: DISCUSSION 
Practice change seeks to improve quality and safety of patient outcomes through 
integration of evidence-based research and clinical practice. The purpose of this nine-week 
quality improvement project was to implement a contingency management protocol within 
treatment-as-usual conditions of MAT. While the purpose of the practice change was to achieve 
optimal compliance rates with the contingency management protocol, with the overall goal was 
to increase abstinence rates within the first 28 days of treatment.  
Staff Compliance and Protocol Revisions 
The compliance rate for Clinical Staff who delivered the positive reinforcement for 
PDSA Cycle 1 was concerning, as the compliance rate was 75% for the delivery of the positive 
reinforcement within 24 hours of a negative drug screen (Figure 2). Compliance with the other 
component of the protocol, explanation of contingency management during intake, maintained a 
strong compliance rate in PDSA Cycle 1. Identifying and addressing compliance issues, along 
with other concerns reducing the intervention’s efficacy, remained a priority for the Project Lead 
during the transitional period between each PDSA cycle. Therefore, developing a solution to 
improve upon the lacking compliance during PDSA cycle 1 became an important objective early 
in the implementation period.  
The structure of PDSA cycles allows for implementation through sequential testing of 
changes and assessment of stakeholder buy-in; the debriefing proved very effective in identifying 
barriers and solutions for the next PDSA cycle (Langley, Moen, Nolan, Norman, & Provost, 
2009). The Project Lead was able to review quantitative compliance results and clinical staff 
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recommendations for modifications to the contingency management protocol between PDSA 
cycles 1 and 2. Qualitative data gathered through debriefing revealed that the contributor for a 
low compliance rate was a barrier involving an LCAS being unprepared for delivery of the 
contingency management. Further investigation suggested that LCASs were not being effectively 
notified and given time to prepare before being expected to deliver the intervention. As a result, 
the Project Lead chose to modify the process to include a formal notification via e-mail, in 
addition to the patient being flagged. Other suggestions, such as the Director of Nursing serving 
as a backup to the program nurse, were acted upon. This led to further, proactive modifications to 
the protocol. As noted by the results of PDSA cycle 2, these revisions ultimately promoted 
compliance and intervention efficiency (Figure 1; Figure 2). Through the process of studying 
results, acting upon them, planning the next cycle, and enacting those changes, the Project Lead 
was able to improve compliance from 75% to 88% between the first two cycles (Figure 2).  
 During PDSA cycle 2, provisional LCASs, in addition to full LCASs who participated in 
PDSA cycle 1, were included in the protocol and able to deliver the intervention. As the 
efficiency of contingency management was improved between the first two cycles, a greater 
number of staff participants were included in the intervention. This was a critical component of 
the implementation process as it allowed the Project Lead to review assessment data for the 
intervention’s sustainability and evaluate potential new barriers that could arise as an increased 
number of clinical staff became involved with contingency management. The inclusion of 
additional staff-participants exposed deficiencies within the protocol which accounted for 
staffing issues. The two significant barriers experienced during PDSA cycle 2 were both related 
to unanticipated staff absences and led to a significant decline in compliance rate for the task of 
explanation of contingency management during the intake process, which fell to 57% (Figure 1). 
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It was also attributed to a decline in compliance for appropriate delivery of positive 
reinforcement, which was 88% for PDSA cycle 2. After evaluation of quantitative and qualitative 
data, similar to the transition between PDSA cycle 1 and 2, the Project Lead was able to 
ameliorate these barriers through revisions of the protocol before the implementation of PDSA 
cycle 3. The consistent increase of participants across all PDSA cycles and the identification of 
barriers associated with increased number of staff-participants provided invaluable insight for 
areas of improvement required for optimal compliance, increased sustainability, and feasible 
implementation on a long-term basis 
During the third cycle, PDSA cycle 3, all full LCASs, provisional LCASs, and CSACs 
were able to deliver positive reinforcement to patients who achieved a negative drug screen. No 
other barriers were identified requiring revisions to the protocol for the final cycle. Staff-
participant compliance for both components of the protocol, explanation of the protocol during 
the intervention and delivery within 24 hours of a negative drug screen, were maintained at 
100% (Figure 1; Figure 2).  
A key contributor for achievement of an optimal rate of compliance was the stakeholder 
buy-in: the team’s willingness to work together, drive change by providing critical feedback 
between PDSA cycles, and remain engaged with the intervention throughout the implantation 
period. Of special note, this high level of engagement occurred while also managing the effects 
of Covid-19. The staff embraced the methodology of the MFI and actively contributed to the 
development of the final iteration of the contingency management protocol, yielding a final staff 
compliance of 100% (Figure 1; Figure 2). The structure of PDSA cycles promoted important 
communication between the Project Lead and the clinical staff participants who effectively 
implemented the intervention. Their ability to be integrally involved in the implementation 
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allowed the participants to feel recognized, important, and invaluable to the intervention’s 
efficacy. The culmination of the participants’ involvement, recommendations, and combined 
efforts is what ultimately drove success, and the findings of this project are aligned with the 
evidence supporting the efficacy of incorporating contingency management into MAT in a 
feasible, sustainable manner that promoted staff adherence (Benishek et al., 2014). 
Patient Outcomes 
 Overall, there were mixed patient outcomes associated with the implementation of 
contingency management. Among the total patients enrolled during the nine weeks in the 
contingency management protocol 43% (n=18) achieved abstinence within the first 28 days of 
treatment. This was a notable improvement when compared to data of the prior new patient 
(intake) cohort from the same clinic, one month prior to implementation of contingency 
management; who achieved an abstinence rate of only 24% within the first month of treatment. 
However, the patient outcomes after implementation of contingency management are similar to 
the results of published literature involving settings of MAT without contingency management. 
For example, a systematic review discussed randomized controlled trials of patients in outpatient 
MAT settings with a 53% abstinence achievement rate and another with substance abuse rates 
above 40% for their patient sample (Timko et al., 2016; Ainscough et al., 2017; Fullerton et al., 
2014).  
 The patient outcomes of the DNP Project do not suggest implementation of contingency 
management encourages patients to achieve their first negative drug screen. However, patient 
outcomes among those who did achieve abstinence, and earned positive reinforcement, indicate 
that . Of the patients who received the interventions, 77% (n=14) maintained abstinence 
throughout the entire implementation period and 89% (n=16) remained in treatment within the 
first 28 days of beginning MAT. This is a significant improvement over data of the previous 
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intake cohort at the clinic, which showed a retention rate of 41% after 28 days of treatment, and 
available data from published literature which found patient retention rates among 72% in 
randomized controlled trials (Timko et al., 2016; Ainscough et al., 2017; Fullerton et al., 2014). 
Unfortunately, there is a lack of data among the available, published literature regarding rates of 
maintained abstinence, though when compared to the clinic’s patient data of past intake cohorts, 
which in some cases demonstrated maintained abstinence rates of 45%, this is a notable 
improvement. The emotional responses from patients receiving the intervention and their 
verbalization of the pride it instilled within them suggests that contingency management can 
serve as a powerful tool for promoting hope and patient encouragement to achieve therapeutic 
goals leading to positive patient outcomes. 
Of interest, the variability of patient outcomes among the three PDSA cycles suggest 
changes made to the contingency management protocol had no effect on further promoting 
positive results (Figure 3). Although revisions to the protocol resulted in optimal staff 
compliance of 100%, there was no improvement in achieved abstinence, as the highest rate 
occurred during the first PDSA cycle. Likewise, patient outcomes among those that did receive 
the intervention after achieving abstinence remained consistent across the three cohorts of each 
PDSA cycle, with similar rates of patient retention and maintained abstinence among each 
cohort. The lack of improvement across each PDSA cycle could be attributed to the great degree 
of variables, including severity of drug use, history of drug use, presence of polysubstance drug 
use, and environmental factors. Examination of these possible factors were beyond the scope of 
this quality improvement initiative. These variables have a significant effect on the prognosis of 
treatment for each patient and play a significant role with the patient outcomes that were being 
assessed with this project. Correlation of patient variables impacting abstinence is beyond the 
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scope of this quality improvement project and further emphasizes the need for continued 
research to better understand factors influencing the efficacy of contingency management. 
In summary, the findings of this quality improvement project, when compared to rates of 
substance use reduction among published literature, does not suggest that implementation of 
contingency management within MAT was associated with a significant improvement of 
achieved abstinence (Timko et al., 2016; Ainscough et al., 2017; Fullerton et al., 2014). 
However, in this setting, contingency management was associated with improved rates of 
maintained abstinence from illicit substance abuse for those who had received positive 
reinforcement, and improved patient retention in the first 28 days of treatment among those that 
had received positive reinforcement.  
Unanticipated Outcomes 
There were several unanticipated reactions to contingency management, all of which 
were related to interpersonal dynamics and the delivery of the positive reinforcement. Patients 
who had reached the identified therapeutic goal had already been informed they were to receive a 
positive reinforcement, as this was explained during the intake process. Contingency 
management theory stipulates that the incentives presented to patients encourage the desired 
behavior and thus achievement of the therapeutic goal. As a result, it was expected among the 
Project Lead, and clinical staff, that the patients who had earned positive reinforcement would be 
most excited about the material prizes. This was not the case, as what elicited the strongest 
reaction from patients was the verbal affirmation they received from the CSAC or LCAS while 
the material incentives were presented. During the debriefings, participants discussed universal 
notions of pride among recipients of contingency management. The patients experienced intense, 
visceral reactions to the affirmation, often eliciting intense emotion. Many stated that this was 
the first time they had felt proud of themselves, with one patient stating, “this is the first time 
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someone has been proud of me in years.” There was a universal feeling of accomplishment and a 
new sense of hope for recovery for recipients after receiving praise from clinical staff. From the 
patient’s perspective, simply being recognized for this small, but critically important 
achievement in the journey of recovery, was paramount. Another factor that was mentioned 
frequently among staff during the debriefings included the notion that many patients had not 
been congratulated or held in high regard for significant periods of time. The implementation of 
contingency management had filled that void by creating the opportunity for staff to recognize, 
congratulate, and honor their achievement. 
A second unanticipated reaction to the intervention came from the clinical staff involved 
with the delivery of the positive reinforcement, the LCASs and CSACs. By the end of the 
implementation period, there were little to no complaints regarding difficulty in maintaining 
compliance towards the expectations of the protocol. During debriefings, staff reiterated that the 
intervention was simple and did not serve as a burden towards completing other clinical 
requirements. Despite its simplicity, the staff reported that meeting with patients who had earned 
the intervention and delivering the reinforcement fostered the development of rapport between 
the clinician and the patient. Participants enjoyed sharing the achievement with their patients, 
and looked forward to formally congratulating and recognizing the importance for an addict in 
achieving their first instance of abstinence. Staff-participants explained that, in some cases, this 
was the first time a patient had been free from illicit substances in years, and that sharing the 
moment with them by delivering contingency management was something special. 
The third unanticipated consequence of contingency management concerned patients who 
were not enrolled into the protocol. Due to the limitations of the project, only new patients who 
enrolled into the MAT program at the clinic were eligible to receive the contingency 
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management intervention. However, by the end of the implementation period, through word-of-
mouth, the great majority of the patient population at the clinic was aware of contingency 
management. Many patients who were past the induction phase of treatment were not only upset 
that such a protocol did not exist when they were new to treatment, but that they were not 
allowed to enroll into the current protocol. Patients who had been in treatment for months, and in 
some cases, years, expressed that they would feel more motivated if contingency management 
were available to them. This unexpected phenomenon stresses the importance of implementing 
quality practice change while remaining cognizant of inclusivity, as an inadvertent consequence 
of the implementation of this intervention was the ostracization of established patients. However, 
this phenomenon also suggests the benefit of contingency management, given how universally 
well received and desirable it appeared for an adult population struggling with opioid use 
disorder. 
Strengths and Limitations 
 The MFI framework and sequential steps of the Plan-Do-Study-Act cycles guided 
development of the protocol before implementation began and promoted evaluation and revision 
of the protocol as indicated throughout the implementation process. This approach engaged 
participants and allowed their contribution to the practice change in real time. A major strength 
of the implementation process was the incorporation of the Model for Improvement, which 
allowed important revisions to be made between each PDSA cycle and ultimately resulted in a 
compliance rate of 100% for all components of the protocol. The Project Lead embraced 
humility, understood the importance of critical feedback, and remained willing to apply changes 
to the protocol based on the feedback received. Prompt attention to concerns of the participants 
and remaining open to feedback during the staff meeting, and between cycle debriefs, improved 
compliance to the project’s protocol. 
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The clinical staff were unfamiliar with contingency management and evidence supporting 
its value, thus they felt skeptical about the intervention. After providing the participants with 
evidence-based literature regarding the efficacy of contingency management and data that 
supports improvement of patient outcomes in similar settings, the participants were inspired to 
engage with the intervention.  
A limitation of the restricted implementation period meant the patient cohort for PDSA 
cycle 3 was limited to completed intakes during week seven, as any enrolled patients during 
weeks eight and nine did not have sufficient time to demonstrate abstinence due to the timeframe 
for implementation. This resulted in a smaller cohort. Further, these new patients were allowed 
only two weeks to demonstrate abstinence, as opposed to four weeks. In order for the third 
cohort to have received 28 days to achieve abstinence, the implementation period would have 
had to have been increased by an additional two weeks. This likely skewed the results of patient 
outcomes for the third cohort.  
Finally, the inability to control for patient variables was a limitation. Hidden variables 
pertaining to the patients’ history, such as the severity of drug use, presence of polydrug abuse, 
and other components of addiction, were not monitored. The differences of these components 
among the patient sample of each PDSA cycle may have had an effect on the treatment 
outcomes. In addition, the presence of environmental factors, particularly COVID-19, had a 
profound effect on the size of intake cohorts. 
Recommendations 
Further recommendations offered by the staff participants include drug screens conducted 
on-site and analyzed the same day they were provided by patients, as opposed to being sent off to 
a third party for analysis. The three-day turn around, led to a delay in receiving their results, and 
thus increased the delay between the date patients had achieved the identified therapeutic goal 
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and the date positive reinforcement was awarded. Any setting that could make use of same-day 
analysis may be able to use contingency management with greater benefit to the patient, as the 
positive reinforcement should ideally be delivered as soon as possible to the date of achieving 
the identified therapeutic goal.  
A second recommendation is to consider involving all patients who had yet to achieve 
abstinence and allowing them to receive contingency management. By limiting eligibility to new 
patients, others may feel ostracized and excluded from interventions designed to promote, 
abstinence, the desired outcome of MAT 
Other recommendations focused on the inclusion of more tangible, rewarding, positive 
reinforcers. Other desired prizes may further motivate patients to achieve therapeutic goals, thus 
promoting positive patient outcomes and increasing the efficacy of contingency management. 
Ideas for highly sought prizes include the allowance of take-home medication after abstinence 
had been demonstrated, eliminating the need for the patient to come to the clinic. Due to 
organizational policy this was not feasible for this improvement project.  
Sustainability 
 This quality improvement practice change was designed to be sustainable for the setting. 
The currently designed protocol is inherently low cost, requires no outside funding, and does not 
consume a significant amount of workforce resources. The Project Lead covered the overhead 
cost for framed certificates to be distributed to patients during the delivery of positive 
reinforcement, and the organization had agreed to cover the honorary breakfast for all 
contingency management recipients. The cost of training at the scheduled meeting was 
insignificant, and all staff were paid their usual hourly wage as the intervention occurred during 
normal working hours. There was no notable increase in clinic workload with the 




 This project has demonstrated contingency management can be implemented within MAT 
in a feasible, sustainable manner that encourages a high rate of staff compliance with effective 
delivery of the intervention. The Model for Improvement served as an effective conceptual 
framework that ultimately allowed for the development of a contingency management protocol 
that resulted in an optimal rate of compliance among clinical staff. The results of the project, in 
terms of patient outcomes, suggest that patients who receive positive reinforcement after 
achieving abstinence have a greater likelihood of maintaining abstinence and remaining within 
treatment when compared to a patient cohort who had not received contingency management the 
28 days before implementation of the project. 
 No other quality improvement project assessing staff compliance rates with the 
incorporation of contingency management with MAT is identified in the literature. Further 
research is required to establish how contingency management is associated with patient 
outcomes. This quality improvement initiative demonstrates the potential for other clinicians to 
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